In a report released yesterday, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Ocular Therapeutix (NASDAQ: OCUL), with a price target of $22. The company’s shares closed yesterday at $5.54.
According to TipRanks.com, Piros ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.3% and a 39.1% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ocular Therapeutix with a $16 average price target.
See today’s analyst top recommended stocks >>
Based on Ocular Therapeutix’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $13.77 million. In comparison, last year the company had a GAAP net loss of $18.69 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
